Literature DB >> 8694803

Expression of heme oxygenase and inducible nitric oxide synthase mRNA in human brain tumors.

E Hara1, K Takahashi, T Tominaga, T Kumabe, T Kayama, H Suzuki, H Fujita, T Yoshimoto, K Shirato, S Shibahara.   

Abstract

Heme oxygenase-1, a key enzyme in heme catabolism, and inducible nitric oxide synthase (iNOS) are responsible for production of carbon monoxide and nitric oxide (NO), respectively. Expression of each enzyme has been shown to be modulated by heme and NO, raising a possibility for the coordinated regulation of the two enzymes. We therefore analyzed the expression levels of both mRNA in humans using brain tumors. Either heme oxygenase-1 or iNOS mRNA was expressed at higher levels in brain tumors compared to the brain tissue, but their expression levels were not apparently correlated. In the brain tumor cell lines, treatment with cytokines increased the expression of iNOS mRNA but not heme oxygenase-1 mRNA, whereas treatment with an NO donor increased the expression of heme oxygenase-1 mRNA but not iNOS mRNA. These results suggest the separate regulation of expression of both enzyme mRNA in humans.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8694803     DOI: 10.1006/bbrc.1996.0999

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

Review 1.  Nitric oxide and angiogenesis.

Authors:  M Ziche; L Morbidelli
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

2.  CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas.

Authors:  Abdeljabar El Andaloussi; Maciej S Lesniak
Journal:  J Neurooncol       Date:  2007-01-10       Impact factor: 4.130

Review 3.  Heme Oxygenases in Cardiovascular Health and Disease.

Authors:  Anita Ayer; Abolfazl Zarjou; Anupam Agarwal; Roland Stocker
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

4.  High expression of heme oxygenase-1 is associated with tumor invasiveness and poor clinical outcome in non-small cell lung cancer patients.

Authors:  Jong-Rung Tsai; Hui-Min Wang; Po-Len Liu; Yung-Hsiang Chen; Ming-Chan Yang; Shah-Hwa Chou; Yu-Jen Cheng; Wei-Hsian Yin; Jhi-Jhu Hwang; Inn-Wen Chong
Journal:  Cell Oncol (Dordr)       Date:  2012-10-10       Impact factor: 6.730

5.  Heme oxygenase-1 accelerates protumoral effects of nitric oxide in cancer cells.

Authors:  Takamitsu Sasaki; Kazuhiro Yoshida; Hideaki Kondo; Hitoshi Ohmori; Hiroki Kuniyasu
Journal:  Virchows Arch       Date:  2005-04-15       Impact factor: 4.064

6.  Knockdown of heme oxygenase-1 promotes apoptosis and autophagy and enhances the cytotoxicity of doxorubicin in breast cancer cells.

Authors:  Xiao-Feng Zhu; Wen Li; Jie-Yi Ma; Nan Shao; Yun-Jian Zhang; Rui-Ming Liu; Wei-Bin Wu; Ying Lin; Shen-Ming Wang
Journal:  Oncol Lett       Date:  2015-09-21       Impact factor: 2.967

Review 7.  Heme oxygenase-1 in tumors: is it a false friend?

Authors:  Alicja Jozkowicz; Halina Was; Jozef Dulak
Journal:  Antioxid Redox Signal       Date:  2007-12       Impact factor: 8.401

8.  Heme oxygenase-1 expression in human gliomas and its correlation with poor prognosis in patients with astrocytoma.

Authors:  Norberto A Gandini; María E Fermento; Débora G Salomón; Diego J Obiol; Nancy C Andrés; Jean C Zenklusen; Julián Arevalo; Jorge Blasco; Alejandro López Romero; María M Facchinetti; Alejandro C Curino
Journal:  Tumour Biol       Date:  2014-03

9.  Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membrane.

Authors:  Mercedes Fernandez; Herbert L Bonkovsky
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

10.  Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene.

Authors:  C Iadecola; F Zhang; R Casey; M Nagayama; M E Ross
Journal:  J Neurosci       Date:  1997-12-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.